Originally published In Press as doi:10.1074/jbc.M111507200 on February 4, 2002
J. Biol. Chem., Vol. 277, Issue 16, 13787-13795, April 19, 2002
Tissue Inhibitor of Metalloproteinase-3 Induces a
Fas-associated Death Domain-dependent Type II
Apoptotic Pathway*
Mark
Bond
§,
Gillian
Murphy¶
,
Martin R.
Bennett**,
Andrew C.
Newby
, and
Andrew H.
Baker
From the
Bristol Heart Institute, Level 7, Bristol
Royal Infirmary, University of Bristol, Bristol BS2 8HW, the
¶ School of Biological Sciences, University of East Anglia,
Norwich NR4 7TJ, the ** Department of Medicine,
Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ,
and the 
Department of Medicine and
Therapeutics, University of Glasgow,
Glasgow G11 6NT, United Kingdom
Received for publication, December 3, 2001, and in revised form, January 29, 2002
 |
ABSTRACT |
Tissue inhibitors of metalloproteinases (TIMPs)
are important regulators of matrix metalloproteinase (MMP) and
adamalysin metalloproteinase activity. We previously
reported that overexpression of TIMP-3 inhibits MMPs and induces
apoptotic cell death in a variety of cell types and demonstrated that
apoptosis is mediated through the N terminus of TIMP-3, which harbors
the MMP inhibitory domain. However, little is known about the
mechanisms underlying TIMP-3-induced apoptosis. Here we
demonstrate that overexpression of TIMP-3 induced activation of
initiator caspase-8 and -9 and promoted caspase-mediated cleavage of
the death substrates poly(ADP-ribose) polymerase and focal adhesion
kinase. Furthermore, TIMP-3 induced mitochondrial activation as
demonstrated by loss of mitochondrial membrane potential and release of
cytochrome c. Intervention studies demonstrated that
overexpression of Bcl-2, the anti-apoptotic mitochondrial
membrane protein, or CrmA, a viral serpin inhibitor of caspase-8,
completely inhibited TIMP-3-induced apoptosis. Furthermore, a
dominant-negative Fas-associated death domain mutant inhibited TIMP-3-induced death substrate cleavage and apoptotic death. Taken together, these results indicate that TIMP-3 overexpression induces a
type II apoptotic pathway initiated via a Fas-associated death domain-dependent mechanism.
 |
INTRODUCTION |
Tissue inhibitors of metalloproteinases
(TIMPs)1 are a family of four
secreted proteins that collectively regulate the activity of the matrix
metalloproteinases (MMPs) and at least some of the adamalysin proteases
(1, 2). TIMPs are thought to fold into a similar two-domain structure,
with each domain folded into three loops constrained by three disulfide
bonds (3-6). The N-terminal domain contains a highly conserved
CXC motif deemed responsible for MMP inhibition, whereas the
smaller C-terminal domain confers specific functions such as the
ability of TIMP-1 to interact with pro-MMP-9 and of TIMP-2 to interact
with pro-MMP-2 (7-13).
TIMPs regulate MMP activity. Thus, TIMPs play important roles in
regulating cellular functions that are dependent on matrix composition
such as invasion, migration, differentiation, and proliferation.
Several additional functions have also been attributed to individual
TIMPs such as regulation of angiogenesis, activation of pro-MMP-2, and
mitogenesis (14-18).
Using adenovirus-mediated gene transfer, we recently demonstrated that
overexpression of TIMP-3 in human vascular smooth muscle cells and
cancer cell cultures reduces cell migration and promotes apoptotic cell
death, the latter being evoked through an unknown mechanism (19, 20).
Furthermore, this unique phenotype induced by TIMP-3 translates to a
beneficial reduction in vascular neointima formation in a human model
of late vein graft failure (21). The pro-death domain of TIMP-3 has
recently been localized to the N terminus, the region associated with
MMP inhibitory activity (22); and it has been proposed, at least in
colon cancer lines, that TIMP-3 promotes death through stabilization of
tumor necrosis factor-
(TNF-
) receptors on the cell surface,
leading to increased susceptibility to apoptosis (23). Interestingly,
deficiency of TIMP-3 in homozygous knockout mice results in enhanced
apoptosis during mammary gland involution (24), suggesting that the
physiological levels of TIMP-3 play an important role in regulating
apoptosis during a number of physiological and pathological processes.
It is therefore important to define the mechanism(s) through which TIMP-3 regulates apoptotic mediators when overexpressed.
Apoptotic cell death can be induced by a variety of stimuli, including
death ligands such as TNF-
, Fas ligand, and TRAIL; DNA-damaging
agents; and loss of matrix attachment in adherence-dependent cells. Many of these stimuli activate the apoptotic cascade through the
action of two distinct initiator caspases, caspase-8 and -9. Caspase-9
is an important regulator of downstream effector caspases (caspase-3,
-6, and -7) in response to signals generated by the mitochondria (25,
26). Its activation requires the formation of a cytosolic complex with
apoptosis protease activating factor, ATP, and cytochrome
c released from the mitochondria (26). Caspase-8 is
typically recruited to activated death receptors via interactions with
adaptor proteins such as FADD, where they form part of the death-inducing signaling complex (27). Two caspase-8-initiated apoptotic signaling pathways have been described (28). A strong activation of caspase-8 in response to death receptor activation can
directly activate downstream effector caspases (type I pathway), whereas a weaker activation of caspase-8 can initiate mitochondrial activation, resulting in mitochondrial membrane depolarization, release
of cytochrome c into the cytosol, and subsequent activation of caspase-9 and effector caspases (type II pathway) (28).
During a type II pathway, the mitochondria act as amplifiers, resulting in additional caspase-8 activation (28).
Here we investigated the cellular mechanism activated by overexpression
of TIMP-3 in primary cultures of both vascular smooth muscle cells
(VSMCs) and a HeLa carcinoma cell line. We show that TIMP-3 induces a
FADD-dependent type II apoptotic signaling pathway.
 |
EXPERIMENTAL PROCEDURES |
Materials
Human embryonic kidney 293 cells were purchased from Microbix
(Toronto, Canada), and HeLa cells were from the European Collection of
Animal Cell Cultures (Salisbury, United Kingdom). All chemicals were
purchased from Sigma (Poole, UK) and were of the highest quality
available. Culture media and additives were obtained from Invitrogen
(Paisley, Scotland). Rabbit anti-human TIMP-3 polyclonal antibody was
purchase from Chemicon International, Inc. (Harrow, UK). Recombinant
human TNF-
and rabbit anti-cleaved poly(ADP-ribose) polymerase
(PARP) (p85) antibody were purchased from Roche Molecular Biochemicals
(Lewes, UK). Anti-CrmA, anti-Bcl-2, anti-focal adhesion kinase (FAK),
and anti-cytochrome c antibodies and caspase substrates and
inhibitors were obtained from CN Biosciences (Nottingham, UK).
Anti-TNF-
antibody was purchased from R & D Systems.
MitoTracker® Orange CMTMRos was obtained from
Molecular Probes, Inc. (Leiden, The Netherlands).
Methods
Cell Culture--
Human embryonic kidney 293 cells were
maintained in minimal essential medium supplemented with 100 units/ml
penicillin, 100 µg/ml streptomycin, and 10% (v/v) fetal calf serum.
Rat smooth muscle cells (SMCs) were prepared from thoracic aortas as
described previously (29). Rat SMCs and HeLa cells were cultured in
Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal
calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. All cells were maintained at 37 °C in an atmosphere of 95% air and 5%
carbon dioxide.
Adenoviral Constructs--
The adenoviral construct
rAd/TIMP-3 has been described previously (30). The control
adenoviral construct rAd/
-galactosidase was a gift from Dr. G. W. G. Wilkinson (University of Wales College of Medicine, Heath
Park, Cardiff, UK). rAd/DN-FADD was a gift from Dr. C. Trautwein
(Department of Gastroenterology and Hepatology, Mediziniche Hochschule
Hannover, Hannover, Germany). The rAd/CrmA adenoviral construct was a
gift from Dr. G. Nabel, and the rAd/Bcl-2 adenoviral construct was a
gift from Dr. J. Uney.
Adenoviral Infection--
Primary rat aortic SMCs (passages
2-4) and HeLa cells were cultured in six-well plates or on sterile
glass coverslips until 80% confluent. An accurate cell number was
determined pre-infection by trypsinization of three wells and counting
using a Neubauer hemocytometer. The remaining wells were infected at
300 (rat SMCs) and 100 (HeLa cells) plaque-forming units (pfu)/cell in
1 ml of fresh complete medium for 2 h. The medium was then
replaced with 2 ml of fresh complete medium and left for the required
length of time prior to analysis. For adenoviral co-infections, cells were pre-infected with either the control adenovirus or the test adenovirus at 50 pfu/cell for 2 h. Cells were then incubated in growth medium for an additional 2 h and subsequently infected with
the second adenovirus at 100 pfu/cell for an additional 2 h, after
which the medium was replaced with fresh complete medium.
Western Blotting--
Total cell lysates were prepared in SDS
lysis buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10%
glycerol, and 1× Complete protease inhibitor mixture (Roche Molecular
Biochemicals)). Protein concentration was determined using a Bio-Rad
micro-BCA protein assay according to the manufacturer's instructions.
Proteins (150 µg) were separated by SDS-PAGE under reducing
conditions and transferred to Bio-Rad polyvinylidene difluoride nylon
membranes. Membranes were blocked in Tris-buffered saline/Tween (200 mM Tris-HCl (pH 7.4), 137 mM NaCl, and 0.2%
Tween 20) containing 5% skim milk powder, followed by incubation with
primary antibody. Following washing with Tris-buffered saline/Tween,
blots were incubated with horseradish peroxidase-conjugated secondary
antibody for 60 min, and immunoreactive proteins were visualized using the enhanced chemiluminescence system (ECL, Amersham Biosciences).
In Situ End Labeling of DNA--
Cells were grown on glass
coverslips and fixed in ice-cold methanol 72 h post-infection.
After air drying, cells were washed twice with 1× TE buffer (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA) and
incubated in labeling mixture (50 mM Tris-HCl (pH 7.2), 10 mM MgSO4, 0.1 mM dithiothreitol,
0.01 mM dATP, 0.01 mM dCTP, 0.01 mM
dGTP, 0.01 mM biotin-dUTP, and 8 units/ml DNA polymerase I (Klenow)) for 15 min at room temperature. Cells were rinsed in 1× TE
buffer, and endogenous peroxidase activity was reduced by incubation in
2% H2O2 for 5 min. After further washing,
biotin was labeled with ExtrAvidinTM-peroxidase conjugate
(1:200). Incubation with diaminobenzidine and subsequent
counterstaining with hematoxylin were carried out to distinguish
between positive apoptotic nuclei containing nicked DNA and
non-apoptotic nuclei.
Cell Death Enzyme-linked Immunosorbent Assay--
Apoptotic cell
death was quantified using a photometric enzyme-linked immunosorbent
assay for the detection of cytoplasmic histo-associated DNA fragments
(Roche Molecular Biochemicals). Briefly, cell lysates were incubated
with a biotin-conjugated anti-histone antibody and a
peroxidase-conjugated anti-DNA antibody for 2 h. Complexes were
captured on streptavidin-coated microtiter plates and quantified
using ABTS colorimetric substrate.
Measurement of Mitochondrial Membrane
Potential--
Mitochondrial membrane potential (
m) was
measured using the MitoTracker® Orange CMTMRos fluorescent
dye (31). Briefly, cells were incubated with MitoTracker®
Orange CMTMRos (150 nM) for 30 min in culture medium at
37 °C and 5% CO2. As a positive control for
m loss, cells were incubated with 2 µM
staurosporine for 2 h. Cells were washed once with
phosphate-buffered saline, collected by centrifugation at 200 × g, and fixed in 2 ml of 4% paraformaldehyde in
phosphate-buffered saline (pH 7.4) for 10 min at 4 °C. Fixed cells
were analyzed by flow cytometry (BD PharMingen FACScan) using CellQuest
acquisition software.
Preparation of Cytosolic Extracts--
Cells were collected by
trypsinization and centrifuged at 200 × g for 5 min at
4 °C. Cells were then washed twice with ice-cold phosphate-buffered
saline (pH 7.4), followed by an additional centrifugation at 200 × g for 5 min. The cell pellet was resuspended in 600 µl
of extraction buffer containing 220 mM mannitol, 68 mM sucrose, 50 mM PIPES-KOH (pH 7.4), 50 mM KCl, 5 mM EGTA, 2 mM
MgCl2, 1 mM dithiothreitol, and Complete
protease inhibitor mixture. After 30 min of incubation on ice, cells
were homogenized with a glass Dounce homogenizer and a small clearance
pestle until the majority of the cells had been disrupted. Cell
homogenates were spun at 14,000 × g for 15 min, and
supernatants were removed and analyzed by Western blotting for
cytochrome c.
 |
RESULTS |
TIMP-3 Overexpression Induces Caspase Activation--
In agreement
with previously published data (19, 21, 22), infection of rat VSMCs and
HeLa cells with a replication-deficient adenovirus expressing human
TIMP-3 (rAd/TIMP-3; 300 and 100 pfu/cell, respectively), but not with
the control adenovirus (rAd/
-galactosidase), induced apoptotic cell
death 48-72 h post-infection (data not shown) (22, 30). TIMP-3-induced
apoptosis was characterized by cell shrinkage, cell rounding,
membrane blebbing, and cell detachment from the substratum. In
situ end labeling staining of rAd/TIMP-3-infected cells
revealed intense brown nuclear staining indicative of fragmented DNA,
with nuclear condensation and fragmentation (data not shown). Cells
expressing TIMP-3 also exhibited phosphatidylserine externalization as
indicated by strong annexin V staining without uptake of propidium
iodide (data not shown).
To characterize the intracellular downstream mechanism(s) activated by
TIMP-3, we first measured the effect of TIMP-3 overexpression on
caspase activity. Primary cultures of both rat VSMCs and HeLa cells
infected with rAd/TIMP-3 exhibited increased effector caspase activity
(50.1 ± 0.5- and 4.5 ± 0.2-fold (n = 3),
respectively; p < 0.05) as measured by cleavage of the
synthetic fluorescent substrate
DEVD-7-amino-4-trifluoromethylcoumarin 72 h post-infection (Fig. 1A). Activation of
initiator caspase-8 and -9 was also analyzed to identify possible
mechanisms through which TIMP-3 initiates the apoptotic cascade. The
activity of caspase-8 as measured by cleavage of
IETD-7-amino-4-trifluoromethylcoumarin was elevated 18.61 ± 1.36- and 2.95 ± 0.36-fold (n = 3), respectively
(p < 0.05) in rat VSMCs and HeLa cells, whereas
cleavage of the caspase-9-specific substrate
LEHD-7-amino-4-trifluoromethylcoumarin was elevated 10.88 ± 1.76- and 2.53 ± 0.35-fold (n = 3), respectively
(p < 0.05) (Fig. 1A). Anti-activated
caspase-8 and -9 antibodies also detected activated caspase-8 (p14) and
caspase-9 (p37) in total HeLa cell lysates infected with rAd/TIMP-3,
but not with rAd/
-galactosidase (Fig. 1B). We performed a
detailed time course experiment to evaluate caspase-8 and -9 cleavage
following TIMP-3 overexpression. The activated fragments of caspase-8
and -9 were first detected 36 h post-infection and were both
detected throughout the remaining time course of the experiment (Fig.
2A).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
TIMP-3 induces caspase activation.
HeLa cells and rat VSMCs were infected with either the control
adenovirus or rAd/TIMP-3 at 100 or 600 pfu/cell, respectively.
A, cell lysates were prepared 72 h post-infection and
analyzed for caspase activity using the quenched fluorescent substrates
indicated. Data are presented as -fold induction of caspase activity
detected in 2 × 106 cells. B, HeLa cell
lysates were analyzed for active caspase-8 and -9 by Western
blotting.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Time course of TIMP-3-induced caspase
activation and death substrate cleavage. A, HeLa cells
were infected with rAd/TIMP-3 (100 pfu/cell), and total cell lysates
were prepared at the times indicated. Cell lysates (150 µg) were
analyzed for activated caspase-8 and -9 and cleavage of PARP and FAK by
Western blotting. B, cells infected with rAd/TIMP-3 were
cultured in the presence of 100 µM
benzyloxycarbonyl-VAD-fluoromethyl ketone (ZVAD) or 100 µM N-acetyl-Leu-Leu-norleucinal
(ALLN). Cell lysates were prepared 72 h post-infection
and analyzed for PARP and FAK cleavage by Western blotting.
|
|
Caspase-mediated cleavage of death substrates is an important event
during the commitment to and execution of apoptotic death. Cleavage of PARP and FAK has previously been reported in numerous cell
types undergoing apoptosis (32, 33). We therefore analyzed PARP and FAK
cleavage status in TIMP-overexpressing cells. Infection of HeLa cells
with rAd/TIMP-3 (but not with rAd/
-galactosidase) resulted in the
formation of two prominent lower molecular mass FAK fragments between
70 and 80 kDa and the appearance of an 85-kDa fragment of PARP detected
with an anti-cleaved PARP antibody (Fig. 2A). Cleaved forms
of FAK and PARP were first detectable 32-36 h after rAd/TIMP-3
infection and increased through the time course of the experiment (Fig.
2A). As expected, overexpression of TIMP-3 preceded the
appearance of PARP and FAK cleavage by ~20 h (Fig. 2A).
The time course of PARP and FAK cleavage mirrored that of initiator
caspase-8 and -9 activation, suggesting that TIMP-3 induces
caspase-mediated cleavage of FAK and PARP. To test this hypothesis,
we incubated HeLa cells overexpressing TIMP-3 with either the
pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone or the calpain peptide inhibitor
N-acetyl-Leu-Leu-norleucinal. Incubation with
benzyloxycarbonyl-VAD-fluoromethyl ketone (but not with
N-acetyl-Leu-Leu-norleucinal) completely inhibited the formation of the lower molecular mass forms of FAK and the p85 PARP
fragment, demonstrating caspase-mediated cleavage of these proteins in
response to TIMP-3 overexpression (Fig. 2B).
TIMP-3 Induces Mitochondrial Activation--
Activation of the
mitochondria and release of cytochrome c into the cytosol
have been shown to participate in activation of caspase-9 (26). As we
observed activation of caspase-9 in response to TIMP-3, we first
measured changes in mitochondrial membrane potential (
m)
using CMTMRos and release of cytochrome c into the cytosol
in rat VSMCs and HeLa cells infected with rAd/TIMP-3. rAd/
-galactosidase-infected rat VSMCs and HeLa cells showed
polarized
m as indicated by a high level of CMTMRos
fluorescence (Fig. 3A). As
expected, treatment with 2 µM staurosporine, a potent stimulus for mitochondrial activation, resulted in a marked reduction in CMTMRos fluorescence in both rat SMCs and HeLa cells, demonstrating a reduction in
m (Fig. 3A). Infection with
rAd/TIMP-3 resulted in a similar reduction in
m (Fig.
3A). Interestingly, TIMP-3 overexpression resulted in a
larger reduction in CMTMRos fluorescence than that evoked by
staurosporine. To confirm these observations, efflux of cytochrome
c into the cytosol, another indicator of mitochondrial
activation, was evaluated (28, 34). Low levels of cytochrome
c were detectable in cytosolic extracts from HeLa cells (but
not from rat VSMCs) infected with the control virus
rAd/
-galactosidase (Fig. 3B). However, infection of both VSMCs and HeLa cells with rAd/TIMP-3 dramatically increased the levels
of cytosolic cytochrome c (Fig. 3B).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
TIMP-3 induces mitochondrial activation.
HeLa cells and rat VSMCs were infected with either the control
adenovirus or rAd/TIMP-3 at 100 or 600 pfu/cell, respectively.
A, 72 h post-infection,  m was measured by
CMTMRos staining and flow cytometry. The percentage of cells with low
m is seen as a shift to weaker CMTMRos fluorescence and was
detected using CellQuest software. Uninfected cells were stimulated
with 2 µM staurosporine for 2 h as a positive
control. B, cytosolic extracts were analyzed for cytochrome
c by Western blotting.
|
|
Bcl-2 and CrmA Block TIMP-3-induced Caspase Activation and Death
Substrate Cleavage--
Numerous reports have described the role of
Bcl-2 as a negative regulator of apoptosis-specific mitochondrial
functions (reviewed in Refs. 35 and 36). The ratio between pro- and
anti-apoptotic Bcl-2 family members is thought to regulate such
functions as permeability transition pore formation and release of
apoptosis inducing factor and cytochrome c into the
cytosol and ultimately activation of caspase-9 (26). To determine
whether mitochondrial activation is an important step in the apoptotic
cascade initiated by TIMP-3, we used an adenoviral vector to
up-regulate Bcl-2. Infection of HeLa cells with rAd/Bcl-2 (but not with
rAd/
-galactosidase) strongly elevated levels of Bcl-2 (Fig.
4A). For coexpression studies,
we pretreated cells with rAd/Bcl-2 prior to rAd/TIMP-3 infection to
allow sufficient inhibitor expression to precede expression of TIMP-3.
Pre-infection with rAd/
-galactosidase prior to co-infection with
rAd/TIMP-3 failed to rescue cleavage of PARP and FAK (Fig.
4B). Pre-infection of HeLa cells with rAd/Bcl-2 prior to
subsequent infection 3 h later with rAd/TIMP-3 blocked TIMP-3-induced cleavage of PARP and FAK death substrates (Fig. 4B). Additionally, overexpression of Bcl-2 inhibited
activation of caspase-9, implying that the mitochondria function as
regulators of caspase-9 activation in response to TIMP-3 (Fig.
4B). Furthermore, Bcl-2 co-overexpression also inhibited
activation of caspase-8, suggesting that TIMP-3-induced caspase-8
activation occurs downstream of mitochondrial activation (Fig.
4B).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
Bcl-2 inhibits TIMP-3-induced apoptosis.
A, HeLa cells were either left uninfected (first
lane) or infected with the control adenovirus
(rAd/ -galactosidase (rAd: gal)) at 100 pfu/cell
(second lane) or with rAd/Bcl-2 (third lane) as
indicated. 72 h post-infection, total cell lysates were prepared
and analyzed for Bcl-2 expression by Western blotting as indicated.
B, HeLa cells were pre-infected with either the control
adenovirus or rAd/Bcl-2 as described under "Methods" and then
infected with either the control adenovirus or rAd/TIMP-3. 72 h
post-infection, total cell lysates were prepared and analyzed for
caspase-9 activation and cleaved PARP and FAK.
|
|
Although we have demonstrated activation of caspase-8 following
adenovirus-mediated overexpression of TIMP-3, we further assessed the
direct involvement of this caspase by co-overexpression of CrmA, a
viral serpin inhibitor of caspase-8 (37), using adenovirus-mediated gene transfer. As expected, infection of HeLa cells with rAd/CrmA (but
not with rAd/
-galactosidase) resulted in high level expression of
CrmA (Fig. 5A). Pre-infection
of HeLa cells with rAd/CrmA (but not with rAd/
-galactosidase)
blocked cleavage of PARP and FAK induced by TIMP-3 and activation of
caspase-8 (Fig. 5B). Furthermore, CrmA expression also
inhibited activation of caspase-9 (Fig. 5B), implying that
TIMP-3-induced caspase-9 activation occurs downstream of caspase-9.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
CrmA inhibits TIMP-3-induced apoptosis.
A, HeLa cells were either left uninfected (first
lane) or infected with the control adenovirus
(rAd/ -galactosidase (rAd: gal)) at 100 pfu/cell
(second lane) or with rAd/CrmA (third lane) as
indicated. 72 h post-infection, total cell lysates were prepared
and analyzed for CrmA expression by Western blotting as indicated.
B, HeLa cells were pre-infected with either the control
adenovirus or rAd/CrmA as described under "Methods" and then
infected with either the control adenovirus or rAd/TIMP-3. 72 h
post-infection, total cell lysates were prepared and analyzed for
caspase-9 activation and cleaved PARP and FAK.
|
|
Dominant-negative FADD Blocks TIMP-3-induced
Apoptosis--
Caspase-8 is typically activated in response to
engagement of death receptors, which contain cytoplasmic death domains
(38, 39). Caspase-8 is recruited to activated death receptors through interactions with the adaptor protein FADD, which contains a C-terminal death domain and an N-terminal death effector domain and which is
responsible for recruitment and activation of caspase-8 (27). To test
whether TIMP-3 induces death receptor-initiated apoptosis through
caspase-8, we used an adenoviral vector expressing a death effector
domain-deleted dominant-negative mutant of FADD (rAd/DN-FADD) (40).
Infection of cells with rAd/DN-FADD resulted in high levels of DN-FADD
expression (Fig. 6A) without
affecting cell morphology and viability (Fig. 6D) or
cleavage of PARP and FAK (Fig. 6, C and D). As
expected, infection of HeLa cells with rAd/DN-FADD (but not with the
control virus) completely blocked the cell detachment and membrane
blebbing (Fig. 6D) and cleavage of PARP and FAK (Fig. 6B) induced by TNF-
, demonstrating that DN-FADD
effectively inhibits apoptosis induced by death receptor engagement.
Infection of HeLa cells with rAd/DN-FADD (but not with
rAd/
-galactosidase) not only prevented the morphological changes
associated with TIMP-3-induced apoptosis (including cell shrinkage and
detachment and membrane blebbing), but also completely blocked cleavage
of PARP and FAK death substrates (Fig. 6, B and
D). In addition, DN-FADD blocked both the basal and
TIMP-3-induced apoptotic cell deaths as measured by a cell death
nucleosome enzyme-linked immunosorbent assay (Fig. 6E),
indicating that death receptor engagement is the initiating signal
during TIMP-3-induced apoptosis.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 6.
DN-FADD inhibits TIMP-3-induced
apoptosis. HeLa cells were pre-infected with the control
adenovirus (rAd/ -galactosidase (rAd: gal)) or
rAd/DN-FADD. A, expression of DN-FADD protein was
measured by Western blotting. Cells were stimulated with 50 ng/ml
TNF- for 6 h and analyzed for cleavage of PARP and FAK by
Western blotting (B) or infected with the control adenovirus
or rAd/TIMP-3 and analyzed for cleavage of PARP and FAK by Western
blotting (C). D, cell morphology was
analyzed by phase contrast microscopy. E, cell death was
also analyzed by nucleosome enzyme-linked immunosorbent assay.
|
|
Analysis of Candidate Receptors--
To define the death
receptor(s) responsible for the transmission of the apoptotic stimuli,
we investigated the expression of known death receptors in response to
TIMP-3 overexpression. It has been hypothesized that stabilization of
TNF-
receptors on the cell surface of colon cancer cells is involved
in the apoptotic cascade initiated by TIMP-3 (23). Additionally, TIMP-3
is a potent inhibitor of TNF-
-converting enzyme, a cell-surface
metalloprotease involved in the processing of cell-surface TNF-
(2). Consistent with this, infection of VSMCs or HeLa cells with
rAd/TIMP-3 (but not with rAd/
-galactosidase) resulted in increased
cell-surface levels of TNF-
(Fig.
7A), presumably through
inhibition of TNF-
-converting enzyme-mediated TNF-
shedding from
the cell surface. To test whether this increase in cell-surface TNF-
is responsible for TIMP-3-induced apoptosis, we used an antibody that
neutralizes the biological actions of TNF-
. As expected, cleavage of
PARP and FAK death substrates in response to recombinant TNF-
was almost completely blocked by co-incubation with 5 µg/ml
TNF-
-neutralizing antibody (Fig. 7B), demonstrating the
efficacy of the antibody. However, incubation with the
TNF-
-neutralizing antibody had no effect on TIMP-3-induced death
substrate cleavage, indicating that TIMP-3-induced apoptosis occurs
independently of TNF-
(Fig. 7B). Furthermore,
co-incubation with recombinant soluble Fas/Fc or soluble TRAIL receptor
also had no effect on TIMP-3-induced apoptosis (data not shown).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 7.
TIMP-3-induced
TNF- -independent apoptosis. A,
HeLa cells and VSMCs were infected with rAd/ -galactosidase
(rAd: gal) and rAd/TIMP-3 and analyzed for cell-surface
TNF- by two-step immunofluorescent staining and flow cytometry
48 h post-infection. B, apoptosis was induced in HeLa
cells by infection with rAd/TIMP-3 or treatment with 50 ng/ml TNF-
and 2 µg/ml cycloheximide. Cells were simultaneously treated with 5 µg/ml TNF- -neutralizing antibody (Anti-TNF- N/A) and
analyzed for induction of apoptosis by Western blotting of cleavage of
PARP and FAK death substrates 72 h after rAd/TIMP-3 infection or
6 h after TNF- treatment.
|
|
 |
DISCUSSION |
Imbalances between the levels of TIMPs and MMPs have been
implicated in the pathogenesis of many diseases such as rheumatoid arthritis, tumor cell invasion and metastasis, atherosclerosis, and
fibrosis. Although imbalances in net proteolytic activity are a major
factor in the progression of these diseases, the additional functions
of TIMPs, including the regulation of apoptosis, are also likely to be
important. The processes regulating cell death are complex and involve
intricate interplay between the extracellular microenvironment, the
cell membrane, and intracellular organelles. MMPs, ADAMs, and
their endogenous inhibitors (TIMPs) are attracting increasing attention
as mediators of apoptotic stimuli through mechanisms including control
of matrix remodeling and anoikis and via regulation of death ligands
and their receptors at the cell surface.
Although there is no direct evidence in the literature for regulation
of apoptosis by physiological levels of TIMP-3, there are ample data to
suggest that dysregulation of TIMP-3 levels, either through increased
endogenous expression or ectopic overexpression or through knockout,
leads to direct effects on apoptotic cell death. For example,
endogenous TIMP-3 levels are high in shoulder regions of advanced
atherosclerotic plaques, the regions at which increased apoptosis of
VSMCs leads to plaque destabilization and rupture (42-44). More direct
evidence is observed in the rare inherited disorder Sorsby's fundus
dystrophy, a degenerative disease of the retina characterized by
thickening of the Bruch's membrane and apoptotic death of the retinal
epithelial pigment cells (45-47). In Sorsby's fundus dystrophy,
mutations in the coding region of TIMP-3, which, interestingly, all
lead to an alteration in the number of cysteine residues, have been
identified (45, 46), although a direct link between altered TIMP-3
activity and/or distribution has not been documented. Induction of
apoptotic cell death by TIMP-3 overexpression is well documented and
has been shown in vascular cells and cancer cells in vitro
and in vivo (19, 23, 30, 48). Beneficial effects of TIMP-3
in these scenarios include modulation of both cell migration and
invasion through MMP blockade, reduced angiogenesis, and elevated rates of apoptosis, the latter through unknown mechanisms. Smith et al. (23) have reported that TIMP-3 induces apoptosis of DLD carcinoma cells via stabilization of cell-surface TNF-
receptors. Interestingly, recent evidence has demonstrated, at least in the mouse,
that the absence of TIMP-3 leads to apoptotic cell death in involuting
breast tissue (24). There is therefore an increasing need to understand
the precise mechanism(s) that TIMP-3 regulates during physiological
processes as well as the signaling pathways activated through TIMP-3
overexpression. The latter is especially important for the potential
exploitation of TIMP-3 as an effective gene-based pro-death therapy for
vascular disease (21) and cancer (48, 49). Modulation of apoptosis by
other metalloproteinase inhibitors has been described (50-52).
Mitsiades et al. (53) have described the induction of
Fas-mediated apoptosis in Ewing's sarcoma cell lines by synthetic
metalloproteinase inhibitors. Additionally, TIMP-4 has recently been
shown to promote apoptosis of transformed cardiac fibroblasts (54).
A large body of evidence demonstrates the major role played by the
caspases in the execution of apoptotic cell death in response to
numerous signals (55). The caspase cascade can be activated via the
activity of two families of initiator caspases. Members of the
caspase-8 family are typically recruited to activated death receptors
via interactions with adaptor proteins such as FADD, where they form
part of the death-inducing signaling complex (27). The caspase-9 family
(caspase-9 and -2) is thought to be important in activating the
downstream effector caspases in response to signals generated by the
mitochondria (25, 26). Caspase-9 activation requires the formation of a
cytosolic complex with APAF, ATP, and cytochrome c released
from the mitochondria (26). Here we have demonstrated that TIMP-3
increased caspase activity and caspase-mediated cleavage of the death
substrates FAK and PARP. Depolarization of the mitochondrial membrane
and release of cytochrome c also suggest that the
mitochondria play an important role in regulating apoptosis induced by
TIMP-3. Interestingly, TIMP-3 induced activation of both initiator
caspase-8 and -9, suggesting that these caspases may play a role in the
initiation of apoptosis by TIMP-3. To identify the initiating signal
and the apical caspase activated by TIMP-3, we employed recombinant adenoviral vectors expressing Bcl-2, a negative regulator of
apoptosis-specific mitochondrial functions (56, 57); CrmA, a cowpox
serpin inhibitor of caspase-8; and DN-FADD, a death receptor adaptor
protein involved in activation of caspase-8 (27). Overexpression of
Bcl-2 completely inhibited activation of caspase-9, demonstrating that
mitochondrial activation is responsible for activation of caspase-9
during TIMP-3-induced apoptosis. TIMP-3 overexpression also resulted in
a drop in mitochondrial membrane potential and a release of cytochrome
c into the cytosol. The importance of this mitochondrial
activation in the progression of TIMP-3-induced apoptosis is
demonstrated by the complete inhibition of death substrate cleavage by
overexpression of Bcl-2. Expression of Bcl-2 also inhibited activation
of caspase-8, suggesting that the majority of caspase-8 activation in
response to TIMP-3 occurs downstream of mitochondrial activation.
Inhibition of caspase-8 activation by Bcl-2 has been described
previously in Jurkat cells that undergo a type II apoptotic pathway in
response to the Fas ligand (28). In cells that undergo a type II
apoptotic pathway, death receptor engagement initially triggers only a
small amount of caspase-8 activation, leading to activation of the
mitochondria, which in turn results in cleavage of caspase-9,
downstream effector caspases such as caspase-3, and ultimately more
caspase-8. In this type of pathway, caspase-8 is the apical caspase,
and the mitochondria function as amplifiers of the caspase cascade. To test whether TIMP-3 induces a similar type II apoptotic mechanism in
HeLa cells, we used an adenovirus carrying CrmA. Infection of HeLa
cells with rAd/CrmA (but not the control virus) inhibited TIMP-3-induced activation of caspase-9 and cleavage of FAK and PARP
death substrates. These data are consistent with the hypothesis that
TIMP-3 induces a type II apoptotic pathway initiated by caspase-8.
Taken together, the data suggest that TIMP-3 induces apoptosis via
a death receptor-mediated mechanism. To confirm this, we used a
dominant-negative mutant of FADD, a protein involved in recruitment of
caspase-8 to the death-inducing signaling complex, where it is
subsequently activated. Apoptosis induced by death ligands such as
TNF-
and Fas ligand have previously been shown to be blocked by
overexpression of DN-FADD mutants that are unable to recruit caspase-8
(58-60). We have shown that infection of HeLa cells with rAd/DN-FADD
completely blocked TNF-
-induced cleavage of FAK and PARP.
Furthermore, expression of DN-FADD also completely inhibited
TIMP-3-induced cleavage of FAK and PARP and the morphological changes
associated with apoptosis such as membrane blebbing and cell
detachment, demonstrating that TIMP-3 induces
FADD-dependent apoptosis. Taken together, these data
strongly suggest that TIMP-3 initiates a type II apoptotic pathway via
a FADD-sensitive death receptor.
Clearly, the identity of the death receptor that mediates
TIMP-3-induced apoptosis is of great interest. Previous studies have
suggested that TNF receptor-1 plays a role in TIMP-3-induced apoptosis of DLD carcinoma cells (23). Here we have reported that
TIMP-3 overexpression resulted in increased levels of cell-surface TNF-
in both VSMCs and HeLa cells. However, neutralization of this
TNF-
had no effect on TIMP-3-induced apoptosis. This probably reflects differences in death receptor and death ligand expression. Furthermore, incubation with recombinant soluble Fas/Fc and soluble TRAIL receptors, which inhibit Fas ligand- and TRAIL-mediated apoptosis
by acting as decoy receptors (41), also failed to block TIMP-3-induced
apoptosis. These data demonstrate that TIMP-3-induced apoptosis in HeLa
cells and VSMCs occurs independently of TNF-
, Fas ligand, or TRAIL.
However, this does not rule out the possibility of ligand-independent
actions of TNF receptor-1 or Fas or TRAIL receptors.
In summary, this study has highlighted the involvement of a
FADD-dependent type II apoptotic pathway in the induction
of apoptosis by TIMP-3. These findings are likely to have important
implications for our understanding of the normal physiological roles of
TIMP-3, the involvement of TIMP-3 in diseases such as Sorsby's fundus dystrophy, and the future development of TIMP-3-based gene therapies.
 |
ACKNOWLEDGEMENT |
We thank Dr. J. Boyle (Department of Medicine,
Addenbrooke's Hospital, University of Cambridge) for help with the
flow cytometric analysis of cell-surface TNF-
.
 |
FOOTNOTES |
*
This work was supported in part by the British Heart
Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 44-117-9283154;
Fax: 44-117-9283581; E-mail: Mark.bond@bris.ac.uk.
Supported by the Wellcome Trust and the Medical Research Council.
Published, JBC Papers in Press, February 4, 2002, DOI 10.1074/jbc.M111507200
 |
ABBREVIATIONS |
The abbreviations used are:
TIMPs, tissue
inhibitors of metalloproteinases;
MMP, matrix metalloproteinase;
TNF, tumor necrosis factor;
FADD, Fas-associated death domain;
VSMCs, vascular smooth muscle cells;
SMCs, smooth muscle cells;
PARP, poly(ADP-ribose) polymerase;
FAK, focal adhesion kinase;
rAd, recombinant adenovirus;
DN, dominant-negative;
pfu, plaque-forming units;
PIPES, 1,4-piperazinediethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Birkedal-Hansen, H.,
Moore, W. G. I.,
Bodden, M. K.,
Windsor, L. J.,
Birkedal-Hansen, B., De,
Carlo, A.,
and Engler, J. A.
(1993)
Crit. Rev. Oral Biol. Med.
4,
197-250[Abstract/Free Full Text]
|
| 2.
|
Amour, A.,
Slocombe, P. M.,
Webster, A.,
Butler, M.,
Knight, C. G.,
Smith, B. J.,
Stephens, P. E.,
Shelley, C.,
Hutton, M.,
Knauper, V.,
Docherty, A. J. P.,
and Murphy, G.
(1998)
FEBS Lett.
435,
39-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Docherty, A. J. P.,
Lyons, A.,
Smith, B. J.,
Wright, E. M.,
Stephens, P. E.,
Harris, T. J. R.,
Murphy, G.,
and Reynolds, J. J.
(1985)
Nature
318,
66-69[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Apte, S. S.,
Mattei, M. G.,
and Olsen, B. R.
(1994)
Genomics
19,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Boone, T. C.,
Johnson, M. J.,
DeClerck, Y. A.,
and Langley, K. E.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2800-2804[Abstract/Free Full Text]
|
| 6.
|
Greene, J.,
Wang, M. S.,
Liu, Y. L. E.,
Raymond, L. A.,
Rosen, C.,
and Shi, Y. N. E.
(1996)
J. Biol. Chem.
271,
30375-30380[Abstract/Free Full Text]
|
| 7.
|
Gomez, D. E.,
Alonso, D. F.,
Yoshiji, H.,
and Thorgeirsson, U. P.
(1997)
Eur. J. Cell Biol.
74,
111-122[Medline]
[Order article via Infotrieve]
|
| 8.
|
Langton, K. P.,
Barker, M. D.,
and McKie, N.
(1998)
J. Biol. Chem.
273,
16778-16781[Abstract/Free Full Text]
|
| 9.
|
Yu, W. H.,
Brew, K., Yu, S. S.,
Meng, Q.,
and Woessner, F.
(1998)
Mol. Biol. Cell
9,
1024
|
| 10.
|
Leco, K. J.,
Khokha, R.,
Pavloff, N.,
Hawkes, S. P.,
and Edwards, D. R.
(1994)
J. Biol. Chem.
269,
9352-9360[Abstract/Free Full Text]
|
| 11.
|
Goldberg, G. I.,
Marmer, B. L.,
Grant, G. A.,
Eisen, A. Z.,
Wilhelm, S.,
and He, C. S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8207-8211[Abstract/Free Full Text]
|
| 12.
|
Wilhelm, S. M.,
Collier, I. E.,
Marmer, B. L.,
Eisen, A. Z.,
Grant, G. A.,
and Goldberg, G. I.
(1989)
J. Biol. Chem.
264,
17213-17221[Abstract/Free Full Text]
|
| 13.
|
Stetler-Stevenson, W. G.,
Krutzsch, H. C.,
and Liotta, L. A.
(1989)
J. Biol. Chem.
264,
17374-17378[Abstract/Free Full Text]
|
| 14.
|
Takigawa, M.,
Nishida, Y.,
Suzuki, F.,
Kishi, J.,
Yamashita, K.,
and Hayakawa, T.
(1990)
Biochem. Biophys. Res. Commun.
171,
1264-1271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Stetler-Stevenson, W. G.,
Bersch, N.,
and Golde, D. W.
(1992)
FEBS Lett.
296,
231-234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Strongin, A.,
Collier, I. E.,
Bannikov, G.,
Marmer, B.,
Grant, G.,
and Goldberg, G.
(1995)
J. Biol. Chem.
270,
5331-5338[Abstract/Free Full Text]
|
| 17.
|
Corcoran, M. L.,
and Stetler-Stevenson, W. G.
(1995)
J. Biol. Chem.
270,
13453-13459[Abstract/Free Full Text]
|
| 18.
|
Hayakawa, T.,
Yamashita, K.,
Ohuchi, E.,
and Shinagawa, A.
(1994)
J. Cell Sci.
107,
2373-2379[Abstract]
|
| 19.
|
Baker, A. H.,
George, S. J.,
Zaltsman, A. B.,
Murphy, G.,
and Newby, A. C.
(1999)
Br. J. Cancer
79,
1347-1355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Ahonen, M.,
Baker, A. H.,
and Kahari, V. M.
(1998)
Cancer Res.
58,
2310-2315[Abstract/Free Full Text]
|
| 21.
|
George, S. J.,
Lloyd, C. T.,
Angelini, G. D.,
Newby, A. C.,
and Baker, A. H.
(2000)
Circulation
101,
296-304[Abstract/Free Full Text]
|
| 22.
|
Bond, M.,
Murphy, G.,
Bennett, M.,
Amour, A.,
Knauper, V.,
and Newby, A. C.
(2000)
J. Biol. Chem.
275,
41358-41363[Abstract/Free Full Text]
|
| 23.
|
Smith, M. R.,
Kung, H. F.,
Durum, S. K.,
Colburn, N. H.,
and Sun, Y.
(1997)
Cytokine
9,
770-780[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Fata, J. E.,
Leco, K. J.,
Voura, E. B., Yu, H. Y. E.,
Waterhouse, P.,
Murphy, G.,
Moorehead, R. A.,
and Khokha, R.
(2001)
J. Clin. Invest.
108,
831-841[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Budihardjo, I.,
Oliver, H.,
Lutter, M.,
Luo, X.,
and Wang, X. D.
(1999)
Annu. Rev. Cell Dev. Biol.
15,
269-290[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Srinivasula, S. M.,
Ahmad, M.,
Alnemri, E. S.,
and Wang, X. D.
(1997)
Cell
91,
479-489[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Ashkenazi, A.,
and Dixit, V.
(1998)
Science
277,
1305-1308
|
| 28.
|
Scaffidi, C.,
Fulda, S.,
Srinivasan, A.,
Friesen, C., Li, F.,
Tomaselli, K. J.,
Debatin, K.,
Krammer, P. H.,
and Peter, M. E.
(1998)
EMBO J.
17,
1675-1687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Bennett, M. R.,
Anglin, S.,
McEwan, J. R.,
Jagoe, R.,
Newby, A. C.,
and Evan, G. I.
(1994)
J. Clin. Invest.
93,
820-828[Medline]
[Order article via Infotrieve]
|
| 30.
|
Baker, A. H.,
Zaltsman, A. B.,
George, S. J.,
and Newby, A. C.
(1998)
J. Clin. Invest.
101,
1478-1487[Medline]
[Order article via Infotrieve]
|
| 31.
|
Macho, A.,
Decaudin, D.,
Castedo, M.,
Hirsch, T.,
Susin, S.,
Zamzami, N.,
and Kroemer, G.
(1996)
Cytometry
25,
333-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Margolin, N.,
Raybuck, S. A.,
Wilson, K. P.,
Chen, W.,
Fox, T., Gu, Y.,
and Livingston, D. J.
(1997)
J. Biol. Chem.
272,
7223-7228[Abstract/Free Full Text]
|
| 33.
|
Levkau, B.,
Herren, B.,
Koyama, H.,
Ross, R.,
and Raines, E. W.
(1998)
J. Exp. Med.
187,
579-586[Abstract/Free Full Text]
|
| 34.
|
Yang, J.,
Liu, X. S.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J. Y.,
Peng, T. I.,
Jones, D. P.,
and Wang, X. D.
(1997)
Science
275,
1129-1132[Abstract/Free Full Text]
|
| 35.
|
Adams, J. M.,
and Cory, S.
(2001)
Trends Biochem. Sci.
26,
61-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Antonsson, B.,
and Martinou, J. C.
(2000)
Exp. Cell Res.
256,
50-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Bennett, M.,
Macdonald, K.,
Chan, S. W.,
Luzio, J. P.,
Simari, R.,
and Weissberg, P.
(1998)
Science
282,
290-293[Abstract/Free Full Text]
|
| 38.
|
Muzio, M.,
Chinnaiyan, A. M.,
Kischkel, F. C.,
O'Rourke, K.,
Shevchenko, A., Ni, J.,
Scaffidi, C.,
Bretz, J. D.,
Zhang, M.,
Gentz, R.,
Mann, M.,
Krammer, P. H.,
Peter, M. E.,
and Dixit, V. M.
(1996)
Cell
85,
817-827[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Srinivasula, S. M.,
Ahmad, M.,
Fernandes-Alnemri, T.,
Litwack, G.,
and Alnemri, E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14486-14491[Abstract/Free Full Text]
|
| 40.
|
Bradham, C.,
Qian, T.,
Streetz, K.,
Trautwein, C.,
Brenner, D.,
and Lemasters, J.
(1998)
Mol. Cell. Biol.
18,
6353-6364[Abstract/Free Full Text]
|
| 41.
|
Rytomaa, M.,
Martins, L.,
and Downward, J.
(1999)
Curr. Biol.
9,
1043-1046[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Fabunmi, R. P.,
Sukhova, G. K.,
Sugiyama, S.,
and Libby, P.
(1998)
Circ. Res.
83,
270-278[Abstract/Free Full Text]
|
| 43.
|
Geng, Y. J.,
and Libby, P.
(1995)
Circulation
92,
471-471
|
| 44.
|
Bjorkerud, S.,
and Bjorkerud, B.
(1996)
Am. J. Pathol.
149,
367-380[Abstract]
|
| 45.
|
Weber, B. H. F.,
Vogt, G.,
Pruett, R. C.,
Stohr, H.,
and Felbor, U.
(1994)
Nat. Genet.
8,
352-356[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
AnandApte, B.,
Bao, L.,
Smith, R.,
Iwata, K.,
Olsen, B. R.,
Zetter, B.,
and Apte, S. S.
(1996)
Biochem. Cell Biol.
74,
853-862[Medline]
[Order article via Infotrieve]
|
| 47.
| Majid, M., Smith, V. A., Easty, D., and Baker, A. (2001) Br.
J. Ophthalmol., in press
|
| 48.
|
Ahonen, M.,
Baker, A. H.,
and Kahari, V. M.
(1998)
Cancer Res.
58,
2310-2315[Abstract/Free Full Text]
|
| 49.
|
Ahonen, M. A.,
Baker, A. H.,
George, S. J.,
Saarialho-Kere, U.,
and Kahari, V. M.
(2000)
J. Invest. Dermatol.
115,
575
|
| 50.
|
Guedez, L.,
Courtmanch, L.,
and Stetler-Stevenson, M.
(1998)
Blood
92,
1342-1349[Abstract/Free Full Text] W. G.
|
| 51.
|
Guedez, L.,
Stetler-Stevenson, W. G.,
Wolff, L.,
Wang, J.,
Fukushima, P.,
Mansoor, A.,
and Stetler-Stevenson, M.
(1998)
J. Clin. Invest.
102,
2002-2010[Medline]
[Order article via Infotrieve]
|
| 52.
|
Gaudin, P.,
Trocme, C.,
Berthier, S.,
Kieffer, S.,
Boutonnat, J.,
Lamy, C.,
Surla, A.,
Garin, J.,
and Morel, F.
(2000)
Biochim. Biophys. Acta
1499,
19-33[Medline]
[Order article via Infotrieve]
|
| 53.
|
Mitsiades, N.,
Poulaki, V.,
Leone, A.,
and Tsokos, M.
(1999)
J. Natl. Cancer Inst.
91,
1678-1684[Abstract/Free Full Text]
|
| 54.
|
Tummalapalli, C. M.,
Heath, B. J.,
and Tyagi, S. C.
(2001)
J. Cell. Biochem.
80,
512-521[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Chang, H. Y.,
and Yang, X. L.
(2000)
Microbiol. Mol. Biol. Rev.
64,
821[Abstract/Free Full Text]
|
| 56.
|
Hockenbery, D.,
Nunez, G.,
Milliman, C.,
Schreiber, R.,
and Korsmeyer, S.
(1990)
Nature
348,
334-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Reed, J.
(1994)
J. Cell Biol.
124,
1-6[Free Full Text]
|
| 58.
|
Chinnaiyan, A. M.,
Tepper, C. G.,
Seldin, M. F.,
O'Rourke, K.,
Kischkel, F. C.,
Hellbardt, S.,
Krammer, P. H.,
Peter, M. E.,
and Dixit, V. M.
(1996)
J. Biol. Chem.
271,
4961-4965[Abstract/Free Full Text]
|
| 59.
|
Wajant, H.,
Johannes, F. J.,
Haas, E.,
Siemienski, K.,
Schwenzer, R.,
Schubert, G.,
Weiss, T.,
Grell, M.,
and Scheurich, P.
(1997)
Curr. Biol.
8,
113-116
|
| 60.
|
Schneider, P.,
Thome, M.,
Burns, K.,
Bodmer, J. L.,
Hofmann, K.,
Kataoka, T.,
Holler, N.,
and Tschopp, J.
(1997)
Immunity
7,
831-836[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao
Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer
Cancer Res.,
June 15, 2008;
68(12):
4736 - 4745.
[Abstract]
[Full Text]
[PDF]
|
 |
|